Sugi Predict

Sugi Predict / Compounds / SCHEMBL825652

SCHEMBL825652

SCHEMBL825652

CCCCCCCCCC(SSC(CCCCCCCCC)(C(=O)O)N1C(=O)CCC1=O)(C(=O)O)N1C(=O)CCC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CES2 O00748 1/20 0.33
▸ FAAH O00519 1/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ SCD O00767 1/20 0.32
▸ GGPS1 O95749 1/20 0.32
▸ PPARG P37231 5/20 0.32
▸ PPARD Q03181 5/20 0.32
▸ PPARA Q07869 5/20 0.32
▸ HDAC11 Q96DB2 4/20 0.32
▸ TSHR P16473 3/20 0.32
▸ GPR84 Q9NQS5 3/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ TLR2 O60603 2/20 0.32
▸ TDP1 Q9NUW8 2/20 0.32
▸ FABP4 P15090 2/20 0.32
▸ PTPN1 P18031 2/20 0.32
▸ SLC22A6 Q4U2R8 1/20 0.32
▸ SLC22A8 Q8TCC7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4302803 1.00 KMT2A (0.37) KMT2ASMN1; SMN2CES2FAAHMGLL
SCHEMBL826506 1.00 KMT2A (0.37) KMT2ASMN1; SMN2CES2FAAHMGLL
SCHEMBL4310964 0.94 KMT2A (0.33) KMT2ASMN1; SMN2MEN1
SCHEMBL378264 0.80 SCD (0.38) KMT2ASMN1; SMN2CES2FAAHMGLL
SCHEMBL7762150 0.78 KMT2A (0.36) KMT2ASMN1; SMN2CES2FAAHMGLL
Hydrochloric Acid SCHEMBL7762499 0.77 KMT2A (0.35) KMT2ASMN1; SMN2CES2FAAHMGLL
SCHEMBL31307518 0.76 KMT2A (0.34) KMT2ASMN1; SMN2CES2FAAHMGLL
SCHEMBL24916383 0.72 MGLL (0.40) KMT2ASMN1; SMN2FAAHMGLLGGPS1
SCHEMBL20930969 0.72 MGLL (0.40) KMT2ASMN1; SMN2FAAHMGLLGGPS1
SCHEMBL21158066 0.72 MGLL (0.40) KMT2ASMN1; SMN2FAAHMGLLGGPS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12618834-B2 Measurement sample preparation method, analysis method, reagent, and reagent kit SYSMEX CORPORATION (JP) 2026-05-05 — — US claimed
EP-4053556-B1 MEASUREMENT SAMPLE PREPARATION METHOD, ANALYSIS METHOD, REAGENT, AND REAGENT KIT SYSMEX CORP (JP) 2025-05-21 — — EP claimed
US-20220283154-A1 MEASUREMENT SAMPLE PREPARATION METHOD, ANALYSIS METHOD, REAGENT, AND REAGENT KIT SYSMEX CORPORATION (JP) 2022-09-08 — — US claimed
EP-4053556-A1 MEASUREMENT SAMPLE PREPARATION METHOD, ANALYSIS METHOD, REAGENT, AND REAGENT KIT SYSMEX CORPORATION (JP) 2022-09-07 — — EP claimed
CN-115014886-A Method for preparing measurement sample, method for analyzing measurement sample, reagent, and kit 希森美康株式会社 2022-09-06 — — CN claimed
EP-3249050-B1 ENZYME ELECTRODE AND BIOSENSOR USING THE SAME ARKRAY INC (JP) 2019-01-23 — — EP claimed
US-20120135891-A1 METHODS AND DEVICES FOR EARLY DETECTION OF CANCER CELLS AND TYPES THROUGH MICROMECHANICAL INTERACTIONS STIHARU, ION 2012-05-31 — — US claimed
US-20080318242-A1 METHODS AND DEVICES FOR EARLY DETECTION OF CANCER CELLS AND TYPES THROUGH MICROMECHANICAL INTERACTIONS STIHARU, ION (CA) 2008-12-25 — — US claimed
US-7270954-B1 Hybridization of target DNA with immobilized nucleic acid analogs IRIS BIOTECHNOLOGIES, INC. (US) 2007-09-18 — — US claimed
US-12618834-B2 Measurement sample preparation method, analysis method, reagent, and reagent kit SYSMEX CORPORATION (JP) 2026-05-05 — — US disclosed
EP-4053556-B1 MEASUREMENT SAMPLE PREPARATION METHOD, ANALYSIS METHOD, REAGENT, AND REAGENT KIT SYSMEX CORP (JP) 2025-05-21 — — EP disclosed
US-20240410885-A1 QMAX ASSAYS AND APPLICATIONS ESSENLIX CORPORATION (US) 2024-12-12 — — US disclosed
US-12066434-B2 QMAX assays and applications ESSENLIX CORPORATION (US) 2024-08-20 — — US disclosed
CN-111936837-B QMAX assay and use 上海宜晟生物科技有限公司 2024-06-07 — — CN disclosed
EP-1097379-A2 MICRODEVICES FOR SCREENING BIOMOLECULES Zyomyx, Inc. (US) 2001-05-09 — — EP disclosed
WO-2001001144-A2 HYBRIDIZATION OF TARGET DNA WITH IMMOBILIZED NUCLEIC ACID ANALOGS IRIS BIO TECHNOLOGIES (US) 2001-01-04 — — WO disclosed
WO-2000070345-A1 REVERSIBLE IMMOBILIZATION OF LIGANDS ONTO METAL SURFACES, THEIR PREPARATION AND USE IN BIOCHEMICAL APPLICATIONS IRIS BIO TECHNOLOGIES (US) 2000-11-23 — — WO disclosed
WO-2000004390-A2 MICRODEVICES FOR SCREENING BIOMOLECULES ZYOMYX, INC. (US) 2000-01-27 — — WO disclosed
WO-2000004382-A1 ARRAYS OF PROTEINS AND METHODS OF USE THEREOF ZYOMYX, INC. (US) 2000-01-27 — — WO disclosed
WO-2000004389-A2 ARRAYS OF PROTEIN-CAPTURE AGENTS AND METHODS OF USE THEREOF ZYOMYX, INC. (US) 2000-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12618834-B2 Measurement sample preparation method, analysis method, reagent, and reagent kit CD63, SLC18A2, EXOSC5 KMT2A 467/4885SMN1; SMN2 1211/4885CES2 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.